Lorem 1psum Is simply dummy text of the printing and typesetting industry Lorem Ipsum has been the industry's Lorem 1psum Is simply dummy text of the printing and typesetting industry Lorem Ipsum has been the industry' standard dumrny text ever since the 150 Os, when an unknown printer took a galley of type and scrambled it to make a type specimen boo lt is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout The point of using Lorem 1psum.
As of Nov 25, 2015 6:16 PM ET
NYSE ERB $1.24
Open: 1.01
Day High: 1.01
Year High: 1.01
Voulme:
Market Cap:
Outstanding:
0.10 8.76%
Prev Close: 1.01
Day Low: 1.01
Year Low: 1.01
17,603
$54,415,194
54,415,194
ERB INTRADAY GRAPHICAL CHART
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when
CLICK TO VIEW
LD Micro Conference This site uses JavaScript for certainJavaScript
Third Quarter Financial Results Call
Annual report
Committed to shareholder responsiveness, communication and providing the most current company information to our Investors.
view all
latest news
30
Sep
ERBA Diagnostics to Commence Trading on OTC Markets' Pink Open Market After Delisting by the NYSE MKT
ERBA Diagnostics to Commence Trading on OTC Markets' Pink Open Market After Delisting by the NYSE MKT MIAMI, Sept. 30, 2016 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (the "Company"), a fully integrated in vitro diagnostics company, previously disclosed that the Company expected the NYSE MKT LLC (the "Exchange") to initiate procedures to delist the Company's common stock, including the issuance of a delisting notice to the Company, and that the Company planned to disclose receipt of such notice.  At market-close on September 29, 2016, the Exchange suspended trading in the Company's common stock.  On September 30, 2016, the Company received the delisting notice from the Exchange stating that the Exchange has determined to commence proceedings to delist the Company's common stock pursuant to Section 1003(d) of the Exchange's Company Guide (the "Company Guide").  Unless the Company requests an appeal of this determination, which the Company does not expect to do at this time, the Exchange will continue to suspend trading and remove the Company's common stock from listing on the Exchange.  As a result of the delisting notice, the Company expects trading in the Company's common stock to commence upon market-open on Monday, October 3, 2016, on the OTC Markets' Pink Open Market under the symbol "ERBA."  The Company can provide no assurance that its common stock will continue to trade on the OTC Markets' Pink Open Market, whether broker-dealers will continue to agree to provide public quotes of the Company's common stock on the OTC Markets' Pink Open Market, whether the trading volume of the Company's common stock will be sufficient to provide for an efficient trading market or whether quotes for the Company's common stock will continue on the OTC Markets' Pink Open Market in the future. About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. (NYSE MKT:ERB), is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets.  The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics.  ERBA Diagnostics' line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing.  www.erbadiagnostics.com Safe Harbor StatementExcept for the historical matters contained herein, statements in this Current Report on Form 8-K are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be preceded by, followed by or otherwise include the words "may," "will," "believes," "expects," "anticipates," "intends," "plans," "estimates," "projects," "could," "would," "should," or similar expressions or statements that certain events or conditions may occur. These forward-looking statements are based largely on the Company's expectations and the beliefs and assumptions of the Company's management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that: the Company's common stock may not continue to trade on the OTC Markets' Pink Open Market; broker-dealers may not continue to agree to provide public quotes of the Company's common stock on the OTC Markets' Pink Open Market; the trading volume of the Company's common stock may not be sufficient to provide for an efficient trading market; quotes for the Company's common stock may not continue on the OTC Markets' Pink Open Market in the future; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.  See also the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC for further discussion of certain risks and uncertainties that could materially and adversely affect the Company's business, operating results or financial condition.   Contact Information Mohan Gopalkrishnan 305 418 2320 Sep 30, 2016
Read More
29
Sep
ERBA Diagnostics, Inc. Announces Inability to Meet Deadline to Regain Compliance With NYSE MKT Continued Listing Standards
ERBA Diagnostics to Present at OneMedForum January 12, 2015 MIAMI LAKES, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB) Chief Executive Officer, Mohan Gopalkrishnan, will present a business overview and update at the OneMedForum investor conference on Monday, January 12th, 2015 at 2:40 pm PST (5:40 pm EST). A live webcast and replay of the presentation will be available on the investor relations section of the Company's corporate website, www.erbadiagnostics.com. The replay of the webcast will be archived for 90 days. About OneMedForum OneMedForum's objective is to assemble the most promising companies and technologies in health and medicine to connect with investors and executives. The 8th Annual OneMedForum will be held at the San Francisco Marriott Marquis, January 12-13th 2015. To learn more about the conference, presenting companies, or investor registration, visit www.onemedconferences.com. About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. (NYSE MKT:ERB) is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets. The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics. ERBA Diagnostic's line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. www.erbadiagnostics.com   Contact Information Mohan Gopalkrishnan 305 418 2320 Jan 05, 2015
Read More
26
Aug
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards MIAMI, Aug. 26, 2016 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE:ERB) (the "Company"), a fully integrated in vitro diagnostics company, announced today that, on August 23, 2016, the Company received a letter from NYSE MKT LLC (the "Exchange") stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide") due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 with the Securities and Exchange Commission.  The letter also states that the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from the Exchange.  In the letter, the Exchange has acknowledged that the Company is already delinquent on its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and has previously submitted a plan of remediation and compliance, as amended (the "Plan").  As previously reported, the Company submitted the Plan to the Exchange and the Exchange accepted the Plan and granted the Company an extension until November 25, 2016 (the "Plan Period") to regain compliance with the continued listing standards of the Company Guide. The Company will be subject to periodic review by the Exchange during the Plan Period.  Failure to make progress consistent with the Plan or to regain compliance with the continued listing standards of the Company Guide by the end of the Plan Period could result in the Company being delisted from the Exchange.  The Company is working diligently to regain compliance with the Company Guide by November 25, 2016. About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. (NYSE:ERB), is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets.  The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics.  ERBA Diagnostics' line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing.  www.erbadiagnostics.com Safe Harbor StatementExcept for the historical matters contained herein, statements in this Current Report on Form 8-K are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be preceded by, followed by or otherwise include the words "may," "will," "believes," "expects," "anticipates," "intends," "plans," "estimates," "projects," "could," "would," "should," or similar expressions or statements that certain events or conditions may occur. These forward-looking statements are based largely on the Company's expectations and the beliefs and assumptions of the Company's management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that: the Company may not make progress consistent with the Plan or Supplement to Plan during the Plan Period; the Company may not be able to regain compliance with the Company Guide by November 25, 2016, which would result in the Company's common stock being delisted by the Exchange; the Exchange may initiate delisting proceedings, which would result in the Company's common stock being delisted by the Exchange; the Company's financial results may take longer to prepare than anticipated; the Company may not be able to file its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2015, March 31, 2016 and June 30, 2016 or its Annual Report on Form 10-K for the year ended December 31, 2015 on or prior to the timeframe set forth above; if the Company does not comply with the timeframe set forth above, then the Company's common stock may be delisted by the Exchange; during the Company's period of noncompliance with Sections 134 and 1101 of the Company Guide, the Company's common stock may be delisted by the Exchange; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.  See also the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC for further discussion of certain risks and uncertainties that could materially and adversely affect the Company's business, operating results or financial condition.  Many of these factors are beyond the Company's control. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in the Company's filings with the SEC, including, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in such filings. Contact Details: Mohan Gopalkrishnan Tel: 305 418 2320 Aug 26, 2016
Read More
view all
sfc filings
16K - 16K
16 March 2017 SACHIN
4 - Statement of changes in beneficial ownership of securities
21 December 2015 ADMIN
4 - Statement of changes in beneficial ownership of securities
02 June 2015 ADMIN
3 - Initial statement of beneficial ownership of securities
07 May 2015 ADMIN
view all
for investor related queries, check our faq page
go to faq page
Subscribe here
Go
Stay Connected
Address
Mallaustrasse 69-73 68219
Mannheim, Germany
© 2016-2017, Erba Mannheim All Rights Reserved
Select Country
International
USA